130 related articles for article (PubMed ID: 24416789)
1. V-ATPase as an effective therapeutic target for sarcomas.
Perut F; Avnet S; Fotia C; Baglìo SR; Salerno M; Hosogi S; Kusuzaki K; Baldini N
Exp Cell Res; 2014 Jan; 320(1):21-32. PubMed ID: 24416789
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitors may reduce tumour resistance.
De Milito A; Fais S
Expert Opin Pharmacother; 2005 Jun; 6(7):1049-54. PubMed ID: 15957961
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and identification of cytotoxic diphyllin glycosides as vacuolar H(+)-ATPase inhibitors.
Zhang Z; Ma J; Zhu L; Zhao Y
Eur J Med Chem; 2014 Jul; 82():466-71. PubMed ID: 24929344
[TBL] [Abstract][Full Text] [Related]
4. Proton Pump Inhibition Enhances the Cytotoxicity of Paclitaxel in Cervical Cancer.
Song T; Jeon HK; Hong JE; Choi JJ; Kim TJ; Choi CH; Bae DS; Kim BG; Lee JW
Cancer Res Treat; 2017 Jul; 49(3):595-606. PubMed ID: 27669706
[TBL] [Abstract][Full Text] [Related]
5. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity.
De Milito A; Canese R; Marino ML; Borghi M; Iero M; Villa A; Venturi G; Lozupone F; Iessi E; Logozzi M; Della Mina P; Santinami M; Rodolfo M; Podo F; Rivoltini L; Fais S
Int J Cancer; 2010 Jul; 127(1):207-19. PubMed ID: 19876915
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Evaluation of Cleistanthin A Derivatives as Potent Vacuolar H(+) -ATPase Inhibitors.
Zhao Y; Lu Y; Ma J; Zhu L
Chem Biol Drug Des; 2015 Oct; 86(4):691-6. PubMed ID: 25677205
[TBL] [Abstract][Full Text] [Related]
7. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump.
Fan S; Niu Y; Tan N; Wu Z; Wang Y; You H; Ke R; Song J; Shen Q; Wang W; Yao G; Shu H; Lin H; Yao M; Zhang Z; Gu J; Qin W
Oncogene; 2013 Mar; 32(13):1682-90. PubMed ID: 22580606
[TBL] [Abstract][Full Text] [Related]
8. Tumor acidity, chemoresistance and proton pump inhibitors.
De Milito A; Fais S
Future Oncol; 2005 Dec; 1(6):779-86. PubMed ID: 16556057
[TBL] [Abstract][Full Text] [Related]
9. V-ATPase is a candidate therapeutic target for Ewing sarcoma.
Avnet S; Di Pompo G; Lemma S; Salerno M; Perut F; Bonuccelli G; Granchi D; Zini N; Baldini N
Biochim Biophys Acta; 2013 Aug; 1832(8):1105-16. PubMed ID: 23579072
[TBL] [Abstract][Full Text] [Related]
10. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
Luciani F; Spada M; De Milito A; Molinari A; Rivoltini L; Montinaro A; Marra M; Lugini L; Logozzi M; Lozupone F; Federici C; Iessi E; Parmiani G; Arancia G; Belardelli F; Fais S
J Natl Cancer Inst; 2004 Nov; 96(22):1702-13. PubMed ID: 15547183
[TBL] [Abstract][Full Text] [Related]
11. Biological effects of a new vacuolar-H,-ATPase inhibitor in colon carcinoma cell lines.
Supino R; Scovassi AI; Croce AC; Dal Bo L; Favini E; Corbelli A; Farina C; Misiano P; Zunino F
Ann N Y Acad Sci; 2009 Aug; 1171():606-16. PubMed ID: 19723111
[TBL] [Abstract][Full Text] [Related]
12. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump.
Lu X; Qin W; Li J; Tan N; Pan D; Zhang H; Xie L; Yao G; Shu H; Yao M; Wan D; Gu J; Yang S
Cancer Res; 2005 Aug; 65(15):6843-9. PubMed ID: 16061667
[TBL] [Abstract][Full Text] [Related]
13. Myrtenal-induced V-ATPase inhibition - A toxicity mechanism behind tumor cell death and suppressed migration and invasion in melanoma.
Martins BX; Arruda RF; Costa GA; Jerdy H; de Souza SB; Santos JM; de Freitas WR; Kanashiro MM; de Carvalho ECQ; Sant'Anna NF; Antunes F; Martinez-Zaguilan R; Souad S; Okorokova-Façanha AL; Façanha AR
Biochim Biophys Acta Gen Subj; 2019 Jan; 1863(1):1-12. PubMed ID: 30279148
[TBL] [Abstract][Full Text] [Related]
14. Identification of Novel Bisbenzimidazole Derivatives as Anticancer Vacuolar (H⁺)-ATPase Inhibitors.
Patil R; Kulshrestha A; Tikoo A; Fleetwood S; Katara G; Kolli B; Seibel W; Gilman-Sachs A; Patil SA; Beaman KD
Molecules; 2017 Sep; 22(9):. PubMed ID: 28926955
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and bioevaluation of heterocyclic derivatives of Cleistanthin-A.
Zhao Y; Zhang R; Lu Y; Ma J; Zhu L
Bioorg Med Chem; 2015 Aug; 23(15):4884-4890. PubMed ID: 26059594
[TBL] [Abstract][Full Text] [Related]
16. Expression and functional role of vacuolar H(+)-ATPase in human hepatocellular carcinoma.
Xu J; Xie R; Liu X; Wen G; Jin H; Yu Z; Jiang Y; Zhao Z; Yang Y; Ji B; Dong H; Tuo B
Carcinogenesis; 2012 Dec; 33(12):2432-40. PubMed ID: 22962303
[TBL] [Abstract][Full Text] [Related]
17. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study.
Goh W; Sleptsova-Freidrich I; Petrovic N
J Pharm Pharm Sci; 2014; 17(3):439-46. PubMed ID: 25224353
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
[TBL] [Abstract][Full Text] [Related]
19. Cancer with low cathepsin D levels is susceptible to vacuolar (H
Kitazawa S; Nishizawa S; Nakagawa H; Funata M; Nishimura K; Soga T; Hara T
Cancer Sci; 2017 Jun; 108(6):1185-1193. PubMed ID: 28317223
[TBL] [Abstract][Full Text] [Related]
20. Exploring the Link between Vacuolar-Type Proton ATPase and Epithelial Cell Polarity.
Sun-Wada GH; Wada Y
Biol Pharm Bull; 2022; 45(10):1419-1425. PubMed ID: 36184498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
